Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board

NHS

News

<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during April 2019

April 2019

 

High Cost Drugs Subgroup (HCDSG)

12.4.19

HCDSG: Dibotermin Alfa recommendation [Link removed - consultation closed] for consultation
This agent has recently been reintroduced to the market and a request to manage its entry across GM was received into HCDSG. A recommendation using the available evidence base is presented for comment, the group are particularly keen to ascertain the appetite for use of this product across GM and whether the criteria proposed within this recommendation cover all intended use. Any figures on expected usage would be useful. Please submit your comments here [Link removed - consultation closed]. This consultation closes at 5pm on Friday 24th May 2019

Formulary and Managed Entry Subgroup (FMESG)

29.4.19

The following actions [Link removed - consultation closed] were proposed at the April 2019  FMESG meeting and will be sent to CSB for support.

  • Ertugliflozin to be added to formulary as an alternative treatment option.
  • The formulary will be updated to reflect NICE clinical guideline NG123L Urinary incontinence and pelvic organ prolapse in women
  • Oral formulations of sodium fusidate to be added to the RAG list as GREEN (following microbiologist advice, non-formulary)
  • Insulin degludec to be added to the grey list, for use only in patients with type 1 diabetes mellitus.

We now seek comments [Link removed - consultation closed] on these proposals.  This consultation period is open until 5pm on Monday 10th June 2019.

11.4.19

Following GM-wide consultation, actions from the January meeting of FMESG have been published. Changes include:

  • Addition of darvadstrocel for complex perianal fistulas in Crohn's disease to the DNP list
  • Removal from the RAG list of non-formulary drugs with a GREEN status.

8.4.19

The following actions were proposed at the March 2019  FMESG meeting and have been sent to CSB for pre-support.

  • Benralizumab for severe eosinophilic asthma to be added to formulary as a RED drug
  • Pentosan polysulfate sodium (Elmiron) to be added to formulary and the grey list as a GREEN (following specialist initiation) drug for use only as a second-line treatment option for bladder pain syndrome, where conservative measures have failed.
  • Ciclosporin 0.1% eye drops (Verkazia®) to be added to the paediatric RAG list as GREEN (following specialist initiation) for treatment of vernal keratoconjunctivitis in patients aged 4 to 18 years old and who are subject to active follow-up (e.g. reviewed every 6 months).

We now seek comments [Link removed - consultation closed] on these proposals.  This consultation period is open until 5pm on Monday 20th May 2019.

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer